These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 34624903)

  • 1. Alpha emitting nuclides in nuclear medicine theranostics.
    Miederer M
    Nuklearmedizin; 2022 Jun; 61(3):273-279. PubMed ID: 34624903
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Oncological theranostics in nuclear medicine].
    Laschinsky C; Herrmann K; Fendler W; Nader M; Lahner H; Hadaschik B; Sandach P
    Radiologie (Heidelb); 2022 Oct; 62(10):875-884. PubMed ID: 36112174
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Theranostic approaches in nuclear medicine: current status and future prospects.
    Filippi L; Chiaravalloti A; Schillaci O; Cianni R; Bagni O
    Expert Rev Med Devices; 2020 Apr; 17(4):331-343. PubMed ID: 32157920
    [No Abstract]   [Full Text] [Related]  

  • 4. Targeted radionuclide therapy: frontiers in theranostics.
    Gallivanone F; Valente M; Savi A; Canevari C; Castiglioni I
    Front Biosci (Landmark Ed); 2017 Jun; 22(10):1750-1759. PubMed ID: 28410143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PSMA-based theranostics for prostate cancer : From imaging to treatment].
    Ilhan H; la Fougère C; Krause BJ
    Urologe A; 2020 May; 59(5):617-625. PubMed ID: 32377764
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Theranostic Advances in Breast Cancer in Nuclear Medicine.
    Vahidfar N; Aghanejad A; Ahmadzadehfar H; Farzanehfar S; Eppard E
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33925632
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments.
    Farolfi A; Fendler W; Iravani A; Haberkorn U; Hicks R; Herrmann K; Walz J; Fanti S
    Eur Urol Oncol; 2019 Mar; 2(2):152-162. PubMed ID: 31017091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theranostic Radiopharmaceuticals: A Universal Challenging Educational Paradigm in Nuclear Medicine.
    Urbain JL; Scott AM; Lee ST; Buscombe J; Weston C; Hatazawa J; Kinuya S; Singh B; Haidar M; Ross A; Lamoureux F; Kunikowska J; Wadsak W; Dierckx R; Paez D; Giammarile F; Lee KH; O JH; Moshe M; Louw L; More S; Nadel H; Lee D; Wahl R
    J Nucl Med; 2023 Jun; 64(6):986-991. PubMed ID: 37142302
    [No Abstract]   [Full Text] [Related]  

  • 9. Prostate Cancer Theranostics: PSMA Targeted Therapy.
    Seifert R; Alberts IL; Afshar-Oromieh A; Rahbar K
    PET Clin; 2021 Jul; 16(3):391-396. PubMed ID: 34053583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prostate-Specific Membrane Antigen (PSMA) Theranostics for Treatment of Oligometastatic Prostate Cancer.
    Plichta KA; Graves SA; Buatti JM
    Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34829977
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Future of Theranostics: An Outlook on Precision Oncology in Nuclear Medicine.
    Langbein T; Weber WA; Eiber M
    J Nucl Med; 2019 Sep; 60(Suppl 2):13S-19S. PubMed ID: 31481583
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Radioligand Theranostics in the Management of Neuroendocrine Tumors.
    Harris AG; Vinik AI; OʼDorisio TM; OʼDorisio MS
    Pancreas; 2020; 49(5):599-603. PubMed ID: 32433395
    [No Abstract]   [Full Text] [Related]  

  • 13. An Impressive Approach in Nuclear Medicine: Theranostics.
    Vahidfar N; Eppard E; Farzanehfar S; Yordanova A; Fallahpoor M; Ahmadzadehfar H
    PET Clin; 2021 Jul; 16(3):327-340. PubMed ID: 34053577
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nuclear medicine theranostics comes of age.
    Herrmann K; Kraus BJ; Hadaschik B; Kunikowska J; van Poppel H; N'Dow J; Sartor O; Oyen WJG
    Lancet Oncol; 2021 Nov; 22(11):1497-1498. PubMed ID: 34735807
    [No Abstract]   [Full Text] [Related]  

  • 15. Terbium radionuclides for theranostic applications in nuclear medicine: from atom to bedside.
    Van Laere C; Koole M; Deroose CM; de Voorde MV; Baete K; Cocolios TE; Duchemin C; Ooms M; Cleeren F
    Theranostics; 2024; 14(4):1720-1743. PubMed ID: 38389843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. General Concepts in Theranostics.
    Nunes RF; Zuppani RMF; Coutinho AM; Barbosa FG; Sapienza MT; Marin JFG; Buchpiguel CA
    PET Clin; 2021 Jul; 16(3):313-326. PubMed ID: 34053576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bench-to-Bedside Theranostics in Nuclear Medicine.
    Jokar N; Assadi M; Yordanova A; Ahmadzadehfar H
    Curr Pharm Des; 2020; 26(31):3804-3811. PubMed ID: 32067609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging Preclinical and Clinical Applications of Theranostics for Nononcological Disorders.
    Assadi M; Jokar N; Yordanova A; Gholamrezanezhad A; Amini A; Abbasi F; Biersack HJ; Amini A; Nabipour I; Ahmadzadehfar H
    PET Clin; 2021 Jul; 16(3):429-440. PubMed ID: 34053586
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Theranostics in Nuclear Medicine: Emerging and Re-emerging Integrated Imaging and Therapies in the Era of Precision Oncology.
    Gomes Marin JF; Nunes RF; Coutinho AM; Zaniboni EC; Costa LB; Barbosa FG; Queiroz MA; Cerri GG; Buchpiguel CA
    Radiographics; 2020 Oct; 40(6):1715-1740. PubMed ID: 33001789
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound-based nanomedicine for molecular imaging of prostate cancer: from diagnostics to theranostics.
    Zhu Y; Sun Y; Duan Y; Chen Y
    Nanomedicine (Lond); 2021 Oct; 16(23):2029-2032. PubMed ID: 34519535
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.